‘’In 2015, when I started Lorven Biologics as an Independent research laboratory in KIIT-TBI, India, I did it with not more than my unbridled enthusiasm for biotechnology and healthcare. Fortunately, this period of steadfast faith in therapeutics and healthcare solutions coincided with the budding Indian Biotechnology industry that time. In 2022, through careful consideration and investment, Lorven Biologics extended its fast-growing operations to manufacturing scale under GMP model and the story began to unfold.

I’m proud of such a significant accomplishment and our numerous advances in novel technologies including the commercial-sized application of peptide biologics, vaccines, and diagnostic products, as well as the green chemistry solutions in API manufacturing withsignificant reduction in carbon footprint. These have fuelled my continued passion for biotechnology and healthcare. Along with the recent construction of Lorven Biologics GMP drug manufacturing facility, we’ve realized that our enriched expertise and commitment to innovation can extend beyond “big pharma CDMO” to those newly emerged biotech labs and even smaller sized specialty pharmaceutical companies adopting cutting-edge healthcare and biotechnology solutions.’’